NEWARK, N.J., April 19, 2012 /PRNewswire-Asia-FirstCall/ --
American Oriental Bioengineering, Inc. (NYSE: AOB), (the "Company"
or "AOB"), a pharmaceutical company dedicated to improving health
through the development, manufacture and commercialization of a
broad range of prescription and over-the-counter ("OTC") products,
today announced that four out of its five manufacturing
subsidiaries are undergoing onsite short notice inspections
directed by China State Food and Drug Administration ("SFDA").
On 4/16/2012 China SFDA circulated
an urgent notice nationwide calling for immediate suspension of
sales and manufacturing of certain capsule products, sparked by the
discovery of thirteen kinds of capsule products with origins from
Qinghai and Changchun, etc. containing chrome far
exceeding humanly tolerable limits .
SFDA directed onsite short notice inspections of a number of
capsule manufacturers, including our following manufacturing
subsidiaries: Guangxi Lingfeng Pharmaceutical ("GLP"), Boke
Pharmaceutical ("Boke"), Harbin Three Happiness Pharmaceutical, and
Changchun Xinan Pharmaceuticals ("CCXA"). Capsules are major
product formulations for above subsidiaries.
The Company is cooperating in SFDA directed inspections, and GLP
has passed the said capsule inspection as of this press
release.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over the counter products.
Safe Harbor Statement
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks
and uncertainties that may cause actual results to differ
materially from those set forth in these statements. The
economic, competitive, governmental, technological and other
factors identified in the Company's filings with the Securities and
Exchange Commission may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or
otherwise.
Contact:
|
|
American Oriental
Bioengineering, Inc.
|
Kewa Luo
|
(646)
367-1765
|
SOURCE American Oriental Bioengineering, Inc.